AI Summary
✦ ClarthaIpca Laboratories is an integrated pharmaceutical manufacturer producing formulations and APIs for Indian therapeutic markets. Formulations across cardiology, dermatology, diabetes, and infectious diseases drive branded and generic sales, while APIs cover anti-malarial, anti-hypertensive, diuretic, DMARD, and anthelmintic therapies. The upcoming dividend may support shareholder returns, but it does not indicate incremental revenue or margin expansion. Revenue grew 8.0%, while profit increased 54.7% and margins improved, indicating operating leverage or a favorable product mix. However, 13.2% ROE is heavily supported by leverage, with debt-to-equity at 8.49, increasing balance-sheet sensitivity. At 38.6 times earnings, the stock appears rich versus its moderate growth rate, despite improved profitability. Neutral sentiment reflects the open question of whether margin gains can persist while elevated leverage constrains financial flexibility.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 18 analysts
Fundamentals
Fundamentals institutional score is 70 using EVA spread proxy 1.2%; growth durability 88.7.
Valuation
Valuation institutional score is 32 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 42 using mean target upside 2.2%; dispersion penalty 13.3; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 78 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 1 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and technical structure provide support, while valuation and analyst consensus remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 22.1% above historical median. Valuation is stable — currently in the strongly overvalued zone (z-score: +1.58). Confidence: 84%.
Live forward EPS implies next-12-month EPS of ₹65.66. Applying the stock's normalized valuation corridor produces a fair range of ₹1,831.26 to ₹2,258.05, with base value near ₹2,088.64 (+23.1% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹65.66
Forward P/E
25.8x
Base Fair Value
₹2,088.64
Fair Range
₹1,831.26 - ₹2,258.05
Upside To Base
+23.1%
Estimate Source
Live forward EPS
Growth Estimate
+341.6%
5Y Average
27.33
Current
38.85
Overvalued
34.39
Undervalued
27.89
5Y Average
15.35
Current
21.82
Overvalued
18.52
Undervalued
11.84
5Y Average
3.14
Current
4.46
Overvalued
3.61
Undervalued
2.67
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CIPLA LTD CIPLAPharmaceuticals | +3.5% | 12.0% | 35.2x Undervalued | -23% vs avg | -3.8% |
TORRENT PHARMACEUTICALS L TORNTPHARMPharmaceuticals | +54.8% | 13.9% | 78.6x Premium | +72% vs avg | +35.8% |
LUPIN LIMITED LUPINPharmaceuticals | +32.0% | 18.5% | 19.4x Undervalued | -57% vs avg | +18.3% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.6x Undervalued | -22% vs avg | +9.4% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.6x Undervalued | -18% vs avg | -15.4% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.7x Fair | -15% vs avg | +30.0% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 90.6x Premium | +99% vs avg | +123.1% |
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 29.5x Undervalued | -35% vs avg | -5.0% |
IPCA LABORATORIES LTD trades in line with peers (38.8x vs avg 45.6x), reflecting a fair valuation within the Pharmaceuticals cohort. Peers include CIPLA LTD, TORRENT PHARMACEUTICALS L, LUPIN LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹1.81K CrMar 2026Latest net profit
₹262 CrMar 2026Latest EPS
₹10.34Mar 2026Net margin
24.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,402 | 1,486 | 1,663 | 1,507 | 1,511 | 1,566 | 1,811 | 1,663 | 1,638 | 1,747 | 1,930 | 1,845 | 1,814 |
| Expenses + | 1,226 | 1,189 | 1,314 | 1,234 | 1,218 | 1,213 | 1,409 | 1,252 | 1,280 | 1,340 | 1,466 | 1,368 | 1,383 |
| Operating Profit | 176 | 298 | 348 | 273 | 292 | 353 | 402 | 411 | 359 | 407 | 465 | 477 | 431 |
| OPM % | 13% | 20% | 21% | 18% | 19% | 23% | 22% | 25% | 22% | 23% | 24% | 26% | 24% |
| Other Income + | 33 | 43 | -3 | 17 | -79 | 15 | 17 | 17 | -260 | 25 | 22 | 18 | -1 |
| Interest | 18 | 31 | 39 | 27 | 24 | 19 | 17 | 10 | 16 | 12 | 11 | 10 | 10 |
| Depreciation | 59 | 60 | 61 | 63 | 62 | 61 | 63 | 63 | 65 | 63 | 67 | 69 | 70 |
| Profit before tax | 132 | 250 | 245 | 200 | 127 | 288 | 339 | 356 | 17 | 357 | 408 | 417 | 350 |
| Tax % | 36% | 33% | 34% | 32% | 49% | 29% | 28% | 25% | 479% | 27% | 25% | 27% | 25% |
| Net Profit + | 85 | 167 | 162 | 137 | 65 | 204 | 244 | 268 | -65 | 262 | 305 | 303 | 262 |
| EPS in Rs | 3.34 | 6.57 | 6.39 | 5.40 | 2.55 | 8.05 | 9.62 | 10.55 | -2.56 | 10.33 | 12.01 | 11.96 | 10.34 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Standalone And Consolidated Financial Results For 1St Quarter Ended 30Th June, 2026